Max Rosett

CFO Max Rosett sold 60,000 IMNM shares ($1.1M) under 10b5-1 plan; stock down 33.0% from 52-week high.

Max Rosett, Chief Financial Officer of Immunome Inc., sold 60,000 shares at $18.23 on 2026-06-15 under a pre-arranged 10b5-1 trading plan adopted on 2025-12-26, reducing his non-derivative holdings to 54,037 shares from 114,037 shares. The sale occurs within a deeply challenged fundamental context: the company reported $0.00 revenue in its latest quarter, a net loss of $-53,839,000.00, and an annual revenue decline of -23.2%. The stock has declined 33.0% from its 52-week high and is down 6.9% over the past 30 days. The transaction is scheduled rather than discretionary, so timing attributions do not apply; however, his prior two same-ticker sales at IMNM on 2026-04-02 (achieving 30-day returns of 3.7% and 1.1%) provide no clear signal of accurate market-timing ability at this ticker. The combination of severe revenue contraction, substantial operating losses, and continued insider stock disposals warrants attention to the company's path to profitability.

CFO Rosett Max sold 65,000 shares (54.6% of pre-transaction holdings) for $1,424,916.08 at IMNM

Rosett Max, CFO of Immunome Inc., executed 2 separate sales totaling 65,000 shares for $1,424,916.08 on 2026-04-02, reducing his holdings from 119,037 shares to 54,037 shares—a 54.6% reduction. The company reported a net loss of $57,457,000 in its latest period, zero quarterly revenue, and a 23.2% annual revenue decline, indicating significant operational stress. The blended sale price of $21.92 is close to the current price of $21.84 and near the 52-week range midpoint, whereas the stock remains down 19.0% from its 52-week high of $26.97. A large programmatic reduction of this magnitude by the company's CFO warrants scrutiny given the underlying financial deterioration and the scale of share disposition relative to remaining holdings.